Omalizumab for Severe Allergic Asthma Treatment in Italy: A Cost-Effectiveness Analysis from PROXIMA Study.

Giorgio Walter CanonicaGiorgio Lorenzo Colombo Rogliani PaolaPierachille SantusClaudia PitottiSergio Di MatteoChiara Martinotti Giacomo Matteo Bruno

Published in: Risk management and healthcare policy (2020)

This study offers a real-world evidence of omalizumab effectiveness in Italy. Despite the high acquisition cost of the innovative drug, omalizumab is a sustainable treatment option for patients with uncontrolled severe allergic asthma.

Keyphrases

chronic obstructive pulmonary disease
allergic rhinitis
randomized controlled trial
early onset
lung function
combination therapy
atopic dermatitis
smoking cessation